Table 2.
Univariate analysis of conducted first‐line therapies
| 60 included patients | 25 patients achieving first remission | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | 3‐y EFS (95% CI) | P value | 3‐y OS (95% CI) | P value | N (%) | 3‐y EFS (95% CI) | P value | 3‐y OS (95% CI) | P value | |
| Chemotherapy | ||||||||||
| P6 | 5 (8) | 0% | 0.008 | 20.0 ± 35.1 | 0.043 | 4 (16) | 0% | 0.001 | 25.0 ± 42.5 | 0.332 |
| VAIA | 15 (25) | 38.9 ± 25.3 | 53.3 ± 25.3 | 10 (40) | 58.3 ± 31.6 | 80.0 ± 24.7 | ||||
| CEVAIE | 37 (62) | 2.7 ± 5.3 | 22.2 ± 14.1 | 10 (40) | 10.0 ± 18.6 | 38.9 ± 33.9 | ||||
| Other | 3 (5) | 1 (4) | 0% | 100% | ||||||
| Response | ||||||||||
| Partial (≥2/3) | 17 (28) | 5.9 ± 11.2 | 0.738 | 23.5 ± 20.2 | 0.532 | 9 (36) | 11.1 ± 20.6 | 0.685 | 44.4 ± 35.5 | 0.101 |
| Minor (≥1/3) | 12 (20) | 16.7 ± 21.2 | 38.9 ± 28.8 | 5 (20) | 40.0 ± 42.9 | 80.0 ± 35.1 | ||||
| Objective (<1/3) | 8 (13) | 12.5 ± 22.9 | 37.5 ± 33.5 | 3 (12) | 33.3 ± 53.3 | 66.7 ± 53.3 | ||||
| Stable disease | 10 (17) | 0% | 20.0 ± 24.7 | 3 (12) | 0% | 33.3 ± 53.3 | ||||
| Progression (≥1/10) | 5 (8) | 20.0 ± 35.1 | 60.0 ± 42.9 | 2 (8) | 50.0 ± 69.4 | 100% | ||||
| No information | 8 (13) | 3 (12) | ||||||||
| High‐dose chemotherapy with stem cell transplant | ||||||||||
| No | 51 (85) | 11.4 ± 8.8 | 0.613 | 32.0 ± 13.1 | 0.991 | 20 (80) | 29.2 ± 20.4 | 0.546 | 68.1 ± 21.2 | 0.051 |
| Yes | 9 (15) | 11.1 ± 20.6 | 19.0 ± 31.4 | 5 (20) | 20.0 ± 35.1 | 0% | ||||
| Hyperthermia in combination with platinum‐based chemotherapy | ||||||||||
| No | 54 (90) | 12.3 ± 9.0 | 0.173 | 30.2 ± 12.7 | 0.403 | 24 (96) | 27.8 ± 18.6 | 0.551 | 54.9 ± 21.0 | 0.651 |
| Yes | 6 (10) | 0% | 33.3 ± 37.6 | 1 (4) | 0% | 100% | ||||
| Best surgery at any time | ||||||||||
| R0 | 5 (8) | 40.0 ± 42.9 | 0.035 | 60.0 ± 42.9 | 0.005 | 5 (20) | 40.0 ± 42.9 | 0.709 | 60.0 ± 42.9 | 0.802 |
| R1 | 16 (27) | 18.8 ± 19.2 | 45.8 ± 26.1 | 14 (56) | 21.4 ± 21.6 | 52.4 ± 28.0 | ||||
| R2 | 19 (32) | 5.3 ± 10.0 | 25.1 ± 21.0 | 4 (16) | 25.0 ± 42.5 | 66.7 ± 53.3 | ||||
| Biopsy only | 19 (32) | 5.3 ± 10.0 | 15.8 ± 16.5 | 2 (8) | 50.0 ± 69.4 | 50.0 ± 69.4 | ||||
| No information | 1 (2) | 1 (4) | ||||||||
| Best surgery at any time in combination with HIPEC | ||||||||||
| R0 | 5 (8) | 40.0 ± 42.9 | 0.123 | 60.0 ± 42.9 | 0.021 | 5 (20) | 40.0 ± 42.9 | 0.866 | 60.0 ± 42.9 | 0.933 |
| R1 | 13 (22) | 15.4 ± 19.6 | 35.2 ± 27.2 | 11 (44) | 18.2 ± 22.7 | 41.6 ± 30.6 | ||||
| R1 + HIPEC | 3 (5) | 33.3 ± 53.3 | 100% | 3 (12) | 33.3 ± 53.3 | 100% | ||||
| R2 | 17 (28) | 5.9 ± 11.2 | 25.5 ± 21.6 | 3 (12) | 33.3 ± 53.3 | 33.3 ± 53.3 | ||||
| R2 + HIPEC | 2 (3) | 0% | 0% | 1 (4) | 0% | 100% | ||||
| Biopsy only | 19 (32) | 5.3 ± 10.0 | 15.8 ± 16.5 | 2 (8) | 50.0 ± 69.4 | 50.0 ± 69.4 | ||||
| No information | 1 (2) | 0 | ||||||||
| Time of best surgery | ||||||||||
| Biopsy only | 19 (32) | 5.3 ± 10.0 | 0.071 | 15.8 ± 16.5 | 0.008 | 2 (8) | 50.0 ± 69.4 | 0.08 | 50.0 ± 69.4 | 0.11 |
| Before Chemotherapy | 7 (12) | 42.9 ± 36.7 | 85.7 ± 25.9 | 5 (20) | 60.0 ± 42.9 | 100% | ||||
| Up to 3rd round | 12 (20) | 8.3 ± 15.7 | 25.0 ± 24.5 | 9 (36) | 11.1 ± 20.6 | 33.3 ± 30.8 | ||||
| After 3rd round | 21 (35) | 0% | 34.2 ± 21.8 | 9 (36) | 0% | 57.1 ± 39.0 | ||||
| Irradiation | ||||||||||
| No | 40 (67) | 5.0 ± 6.7 | 0.228 | 20.6 ± 12.7 | 0.021 | 16 (64) | 22.2 ± 27.2 | 0.591 | 44.4 ± 32.5 | 0.798 |
| Yes | 20 (33) | 25.0 ± 19.0 | 53.7 ± 22.3 | 9 (36) | 31.3 ± 22.7 | 67.3 ± 23.5 | ||||
| Metronomic chemotherapy | ||||||||||
| No maint. | 6 (24) | 0% | 0.056 | 33.3 ± 37.6 | 0.193 | |||||
| O‐TIE | 11 (44) | 24.2 ± 27.0 | 51.9 ± 30.8 | |||||||
| Cyc/Vbl | 5 (20) | 60.0 ± 42.9 | 80.0 ± 35.1 | |||||||
| Irinotecan‐containing | 3 (12) | 33.3 ± 53.3 | 100% | |||||||
| N (%) | 3‐y RFS (95% CI) | P value | ||||||||
| Metronomic chemotherapy evaluated in patients who achieved a first remission | ||||||||||
| No maint. | 6 (24) | 0% | 0.006 | |||||||
| O‐TIE | 11 (44) | 12.1 ± 21.8 | ||||||||
| Cyc/Vbl | 5 (20) | 60.0 ± 42.9 | ||||||||
| Irinotecan‐containing | 3 (12) | 66.7 ± 53.3 | ||||||||
RFS, relapse‐free survival calculated from end of intensive therapy.
P values are printed in italics, significant P values are bold (P < 0.05).